Showing 6261-6270 of 19379 results for "".
UMMA Clinic: Bridging Cultural Divides Through Health Care
https://reachmd.com/programs/clinicians-roundtable/umma-clinic-bridging-cultural-divides-through-health-care/4615/In 1992, after the verdict was handed down in the Rodney King trial, there were six days of rioting in south Los Angeles. Thousands were injured, more than 50 people were killed, and the city saw approximately one billion dollars in property damage. One of the few bright spots during this dark timeTissue-Engineered Trachea Transplantation
https://reachmd.com/programs/focus-on-future-medicine-and-genetics/tissue-engineered-trachea-transplantation/4105/Recently, scientists were able to engineer for the first time a trachea developed from a patient's own stem cells, wherein a donor's trachea was lined with the patient's stem cells to prevent transplant rejection. Immunosuppressive therapy was not necessary, and the patient remains in good conditionThe Role of Allergists at the Grassroots of Medicine and Public Health
https://reachmd.com/programs/hot-topics-in-allergy/the-role-of-allergists-at-the-grassroots-of-medicine-public-health/4027/How are Medicare and health insurance companies affecting physicians and their patients' access to care? What can physicians do to influence policy at the local level? Dr. J. Allen Meadows, clinical instructor in the Montgomery Internal Medicine Residency Program at the University of Alabama at BirmProstate Cancer Predictability: Can We Anticipate a Patient's Risk in 25 Years?
https://reachmd.com/programs/clinicians-roundtable/prostate-cancer-predictability-can-we-anticipate-patients-risk-25-years/2987/Can you predict a man’s risk of prostate cancer 25 years in the future? The data from this study indicates that PSA levels before age 50 is an indicator of future prostate cancer. Find out more about the prospective study conducted by a team of researchers from Memorial Sloane Kettering. EpidemiologCDC Response to MRSA
https://reachmd.com/programs/clinicians-roundtable/cdc-response-to-mrsa/2024/Our guest, Dr. John Jernigan discusses the CDC's response to MRSA with host, Dr. Bill Rutenberg. Topics included: resources available, education & training, measuring impact and measuring adhearance.Personalizing Treatment for Chronic Ocular Surface Pain
https://reachmd.com/programs/eye-on-ocular-health/personalizing-treatment-for-chronic-ocular-surface-pain/37274/Treating chronic ocular surface pain (COSP) requires more than a one-size-fits-all approach. Many patients fail to respond to initial over-the-counter therapies, so when they seek prescription care, it's important to diagnose their condition correctly and fully understand the underlying mechanisms dHow Early Decisions in Upper GI Cancer Shape Long-Term Outcomes
https://reachmd.com/programs/project-oncology/early-decisions-in-upper-gi-cancer-outcomes/39962/Earlier-line treatment decisions in gastric, gastroesophageal junction, and esophageal cancers can significantly influence long-term outcomes and future therapeutic options. That’s why Dr. Sunnie Kim joins Dr. Alexandria May to review practice-changing data from trials like MATTERHORN and CheckMateUpdates in Energy Based Devices: Strategies for Stacking Treatments
https://reachmd.com/topics/energy-based-devices/updates-in-energy-based-devices-strategies-for-stacking-treatments/54797/Dr. Lanna Cheuck highlights combination treatment advancements incorporating energy-based devices she observed on a recent trip to South Korea.Empowering Patients with CIDP: Education, Support, and Personalized Care Strategies
https://reachmd.com/programs/frontlines-cidp/empowering-patients-with-cidp-education-support-and-personalized-care-strategies/33071/Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) presents unique challenges for newly diagnosed patients and their caregivers. Meeting patients where they are, identifying common misconceptions, and providing effective and individualized education can go a long way in creating an engDESTINY-Breast11 and Neoadjuvant Care in HER2-Positive Breast Cancer
https://reachmd.com/programs/frontlines-metastatic-breast-cancer/destiny-breast11-neoadjuvant-care-her2-positive-breast-cancer/39722/The DESTINY-Breast11 trial explored a neoadjuvant treatment approach for patients with high-risk, HER2-positive early-stage breast cancer. This phase III study compared standard chemotherapy with regimens incorporating T-DXd, aiming to optimize efficacy while potentially reducing toxicity. Hear Dr.